Literature DB >> 11817706

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

D F Stefanik1, W K Fellows, L R Rizkalla, W M Rizkalla, P P Stefanik, A B Deleo, W C Welch.   

Abstract

Monoclonal antibodies raised to peptide sequences of vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibited the growth of C6 tumors growing subcutaneously in nude mice. Immunohistochemical analysis demonstrated antibody targeting of blood vessels, tumor cells, and macrophages. A control antibody demonstrated no growth inhibition or tumor uptake. An antibody to FLT- I impaired microvascular maturation and diminished the accumulation of tumor infiltrating macrophages. The antibodies demonstrated affinity for microvasculature and tumor cells in immunohistochemistry of human glioblastoma multiforme. Targeting VEGF and its receptors has potential in the treatment of tumors of the central nervous system. FLT-1 presents an attractive target due to its presence on multiple cell types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817706     DOI: 10.1023/a:1013329832067

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

1.  ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Authors:  S R Wedge; D J Ogilvie; M Dukes; J Kendrew; J O Curwen; L F Hennequin; A P Thomas; E S Stokes; B Curry; G H Richmond; P F Wadsworth
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

2.  Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells.

Authors:  C Herold-Mende; H H Steiner; T Andl; D Riede; A Buttler; C Reisser; N E Fusenig; M M Mueller
Journal:  Lab Invest       Date:  1999-12       Impact factor: 5.662

3.  [Functional expression of vascular endothelial growth factor receptor Flt-1 on squamous cell carcinoma of the head and neck].

Authors:  C Herold-Mende; T Andl; F Laemmler; C Reisser; M M Mueller
Journal:  HNO       Date:  1999-08       Impact factor: 1.284

4.  Expression of vascular endothelial growth factor receptors in human prostate cancer.

Authors:  F A Ferrer; L J Miller; R Lindquist; P Kowalczyk; V P Laudone; P C Albertsen; D L Kreutzer
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

5.  Oncotic pressure in solid tumors is elevated.

Authors:  M Stohrer; Y Boucher; M Stangassinger; R K Jain
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

6.  Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.

Authors:  B Barleon; G Siemeister; G Martiny-Baron; K Weindel; C Herzog; D Marmé
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

7.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

8.  Factor VII related antigen as an endothelial cell marker in benign and malignant diseases.

Authors:  M Sehested; K Hou-Jensen
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

9.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

10.  Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours.

Authors:  V Speirs; S L Atkin
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  32 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

Authors:  B Neyns; J Sadones; C Chaskis; M Dujardin; H Everaert; S Lv; J Duerinck; O Tynninen; N Nupponen; A Michotte; J De Greve
Journal:  J Neurooncol       Date:  2010-09-25       Impact factor: 4.130

Review 3.  Use of bevacizumab in recurrent glioblastoma.

Authors:  Ashley Ghiaseddin; Katherine B Peters
Journal:  CNS Oncol       Date:  2015-04-23

4.  Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?

Authors:  Annick Desjardins
Journal:  Nat Rev Neurol       Date:  2015-07-21       Impact factor: 42.937

Review 5.  Towards personalized therapy for patients with glioblastoma.

Authors:  Katsuyuki Shirai; Arnab Chakravarti
Journal:  Expert Rev Anticancer Ther       Date:  2011-12       Impact factor: 4.512

6.  Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.

Authors:  Julie A Carlson; Krishna Reddy; Laurie E Gaspar; Douglas Ney; Brian D Kavanagh; Denise Damek; Kevin Lillehei; Changhu Chen
Journal:  J Neurooncol       Date:  2015-04-29       Impact factor: 4.130

7.  Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Authors:  David A Reardon; James J Vredenburgh; April Coan; Annick Desjardins; Katherine B Peters; Sridharan Gururangan; Sith Sathornsumetee; Jeremy N Rich; James E Herndon; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-07-09       Impact factor: 4.130

Review 8.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

9.  Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.

Authors:  Yazmin Odia; Joanna H Shih; Teri N Kreisl; Howard A Fine
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

10.  Glioblastoma multiforme.

Authors:  Herbert B Newton
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.